| Literature DB >> 26981117 |
N Harathi1, Madhusudana Pulaganti1, C M Anuradha2, Suresh Kumar Chitta1.
Abstract
The increasing resistance to anti-tb drugs has enforced strategies for finding new drug targets againstEntities:
Year: 2016 PMID: 26981117 PMCID: PMC4769735 DOI: 10.1155/2016/9841250
Source DB: PubMed Journal: Adv Bioinformatics ISSN: 1687-8027
Figure 1Diagrammatic representation of reaction catalyzed by RmlA from Mtb.
List of selected templates obtained from PDB for modeling Mtb-RmlA model.
| Templates | Chain | Model | Number of residues in templates | Resolution Å | Percentage similarity |
|
|---|---|---|---|---|---|---|
| 1H5T | A | X-ray | 293 | 1.9 | 62 | 0.174 |
| 1H5S | D | X-ray | 293 | 2.3 | 62 | 0.176 |
| 1H5R | B | X-ray | 293 | 1.9 | 63 | 0.173 |
| 1IIM | A | X-ray | 292 | 2.1 | 60 | 0.198 |
Figure 2(a) Multiple sequence alignment of Mtb-RmlA and the templates 1H5T, 1H5R, 1H5S, and 1IIM. Dashes represent insertions and deletions. Highly conserved residues are represented in rectangular boxes. (b) The developed 3D model of Mtb-RmlA shown in cartoon representation with helices in cyan, sheets in magenta, and turns in wheat.
Figure 3(a) Graphical representation of RMSD of back bone carbons from starting structure of Mtb-RmlA as a function of time. (b) The potential energy curve of the system during the MD simulation for Mtb-RmlA. (c) RMS fluctuations for the total protein of Mtb-RmlA.
Figure 4(a) Ramachandran plot for predicted Mtb-RmlA model. (b) ProsA-web Z-scores of all protein chains in PDB determined by X-ray crystallography (light blue) and NMR spectroscopy (dark blue) with respect to their length. The Z-score of Mtb-RmlA was present in that range represented in large black dot. (c) Energy plot for the predicted Mtb-RmlA model.
Procheck values for the predicted Mtb-RmlA model and the template structures.
| Ramachandran plot statistics | 1H5T (Achain) | 1H5S (Dchain) | 1H5R (Bchain) | 1IIM (A hain) | Mtb-RmlA |
|---|---|---|---|---|---|
| % amino acids in most favored regions | 91.5% | 89.9% | 93.5% | 92.3% | 95.4% |
| % amino acids in additional allowed regions | 8.1% | 9.7% | 6.1% | 7.3% | 4.2% |
| % amino acids in generously allowed regions | 0.0%. | 0.0% | 0.0% | 0.0% | 0.0% |
| % amino acids in disallowed regions | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% |
| ProsA | −9.11 | −9.15 | −8.63 | −8.93 | −7.11 |
| RMS | |||||
| Bond angles | 0.934 | 0.890 | 0.894 | 0.709 | 1.185 |
| Bond lengths | 0.775 | 0.751 | 0.690 | 0.369 | 0.910 |
| Errat score | 94.286 | 95 | 98.925 | 98.571 | 92.143 |
Figure 5(a) Errat score for the Mtb-RmlA model. (b) The 3D profile verified results of predicted Mtb-RmlA model. The residues with positive compatibility score are reasonably folded. (c) Diagrammatic presentation of Mtb-RmlA model demonstrating various secondary structural elements. “∗” represents the conserved regions and “∗∗” represents the semiconserved regions.
Main chain and side chain values for Mtb-RmlA obtained from Procheck.
| Stereochemical parameter | Number of data points | Parameter value | Typical value | Band width | Number of band widths from mean |
|---|---|---|---|---|---|
| Main chain stereochemistry | |||||
| % of tag residues | 241 | 95.4 | 83.8 | 10.0 | 1.2 |
| Omega angle SD | 286 | 3.6 | 6.0 | 3.0 | −0.8 |
| Bad contacts/100 residues | 3 | 1.0 | 4.2 | 10.0 | −0.3 |
| Zeta angle SD | 255 | 1.4 | 3.1 | 1.6 | −1.1 |
| H-bond energy SD | 184 | 0.7 | 0.8 | 0.2 | −0.4 |
| Overall | 288 | 0.0 | −0.4 | 0.3 | 1.3 |
| Side chain stereochemistry | |||||
| Chi-1 gauche minus st dev | 29 | 7.3 | 18.1 | 6.5 | −1.7 |
| Chi-1 trans st dev | 78 | 8.4 | 19.0 | 5.3 | −2.0 |
| Chi-1 gauche plus st dev | 108 | 6.9 | 17.5 | 4.9 | −2.2 |
| Chi-1 pooled st dev | 215 | 7.7 | 18.2 | 4.8 | −2.2 |
| Chi-2 trans st dev | 63 | 8.3 | 20.4 | 5.0 | −2.4 |
The parameter value in table represents observed value for Mtb-RmlA compared with typical value obtained for well-refined structure at same resolution.
Figure 6(a) Organization of NTP-transferase domain in Mtb-RmlA model with Scansite server. (b) Organization of various domains in NTP-transferase domain (2–239).
Summary of docking results of ligands to the Mtb-RmlA model.
| Compound Ethambutol | Free energy of binding (kcal/mol) | Docked energy (kcal/mol) | RMSD (Å) |
|---|---|---|---|
| EMB-1 | −6.04 | −8.88 | 0.13 |
| EMB-2 | −5.82 | −8.66 | 0.54 |
| EMB-3 | −5.68 | −8.37 | 0.61 |
| EMB-4 | −5.34 | −8.02 | 0.75 |
| EMB-5 | −4.92 | −7.73 | 0.98 |
| EMB | −4.90 | −7.69 | 1.54 |
| Natural substrate (Glc-1-P) | −6.01 | −8.85 | 0.19 |
Figure 7(a) Interaction of EMB-1 ligand with active site amino acids of Mtb-RmlA model. (b) Interaction of EMB ligand with active site amino acids of Mtb-RmlA model. (c) Interaction of natural substrate (Glc-1-P) with active site amino acids of Mtb-RmlA model. Built model of Mtb-RmlA is represented in cartoon. Ligands and the residues interacting with ligands are represented by sticks.